MétaCan
Menu
← Back to cohort
Record W3016102083 · doi:10.1016/j.cjco.2020.04.002

Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome

2020· review· en· W3016102083 on OpenAlexafffund
David Fitchett, Lawrence A. Leiter, Peter Lin, Jennifer Pickering, Robert C. Welsh, James A. Stone, Jean‐Claude Grégoire, Philip A. McFarlane, Anatoly Langer, Anil Kumar Gupta, Shaun G. Goodman

Bibliographic record

VenueCJC Open · 2020
Typereview
Languageen
FieldMedicine
TopicLipoproteins and Cardiovascular Health
Canadian institutionsUniversity of CalgaryTrillium Health CentreUniversité de MontréalUniversity of AlbertaCanadian VIGOUR CentreUniversity of TorontoHamilton Health SciencesMontreal Heart InstituteCanadian Heart Research CentreSt. Michael's Hospital
FundersDuke Clinical Research InstituteAmerican RegentBristol-Myers Squibb CanadaEsperion TherapeuticsGlaxoSmithKlineHLS TherapeuticsBayerServierUniversity of TorontoNovo NordiskDaiichi-SankyoBayer CanadaRegeneron PharmaceuticalsHDL TherapeuticsValeant Pharmaceuticals InternationalAstraZeneca CanadaActelion PharmaceuticalsYork UniversityPfizerHeart and Stroke Foundation of CanadaNovartisSanofiMerckBoehringer IngelheimAmgenCSL BehringAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsAcute coronary syndromeMedicineEzetimibeResidual riskEicosapentaenoic acidType 2 diabetesProprotein convertaseClinical trialStatinSecondary preventionInternal medicineTicagrelorPioglitazonePharmacologyDiabetes mellitusCholesterolEndocrinologyLipoproteinMyocardial infarctionFatty acidPolyunsaturated fatty acidBiochemistry

Abstract

fetched live from OpenAlex

A recent acute coronary syndrome provides an opportunity to optimise secondary prevention strategies to reduce the risk of future cardiovascular events. This review provides an updated synopsis of current evidence-based approaches. New clinical trial data on the use of antiplatelet and anticoagulants allow choices of the selection and duration of treatment. Lipid lowering after an acute coronary syndrome is now enhanced, with proprotein convertase subtilisin-kexin type 9 inhibitors providing added benefit on top of statin and ezetimibe treatment in high-risk patients. In addition, a recent trial of icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid, addresses residual risk in patients with elevated triglycerides already treated with statins. The use of both sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes reduces cardiovascular events independently of glucose lowering.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.013
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.010
Threshold uncertainty score0.035

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.013
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0030.003
Science and technology studies0.0000.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0100.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.065
GPT teacher head0.375
Teacher spread0.310 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2020
Admission routes2
Has abstractyes

Explore more

Same venueCJC Open→Same topicLipoproteins and Cardiovascular Health→French-language works237,207→